Cargando…

Viro-Immunological, Clinical Outcomes and Costs of Switching to BIC/TAF/FTC in a Cohort of People Living with HIV: A 48-Week Prospective Analysis

To date, therapeutic switches are performed to reduce and prevent toxicity, improve adherence, promote virological control, and save costs. Drug switches are a daily challenge in the management of people living with HIV (PLWH), especially in those with multiple comorbidities and on polypharmacy. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mazzitelli, Maria, Trunfio, Mattia, Putaggio, Cristina, Sasset, Lolita, Leoni, Davide, Lo Menzo, Sara, Mengato, Daniele, Cattelan, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405513/ https://www.ncbi.nlm.nih.gov/pubmed/36009370 http://dx.doi.org/10.3390/biomedicines10081823

Ejemplares similares

Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV
por: Mazzitelli, Maria, et al.
Publicado: (2023)

1598. Predictive equations for immune recovery at 48 weeks of BIC/FTC/TAF treatment in Virologically Suppressed PLWHIV.
por: Tomé, Roberto Pedrero, et al.
Publicado: (2023)

1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.
por: Estévez, Samuel, et al.
Publicado: (2023)

Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis
por: Mazzitelli, Maria, et al.
Publicado: (2021)

Short-term Adverse Events With BIC/FTC/TAF: Postmarketing Study
por: Hayes, Edwin, et al.
Publicado: (2020)

2508. Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance
por: Natali, Kayla M, et al.
Publicado: (2019)

Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
por: Mazzitelli, Maria, et al.
Publicado: (2023)

1448. Forgiveness of BIC/FTC/TAF: In Vitro Simulations of Intermittent Poor Adherence Find Limited HIV-1 Breakthrough and High Barrier to Resistance
por: Mulato, Andrew, et al.
Publicado: (2020)

1003. BIC/FTC/TAF Maintains Viral Suppression in Patients with Documented M184V/I Mutations: A Real World Experience
por: Chamberlain, Nicholas, et al.
Publicado: (2020)

1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF
por: McKellar, Mehri, et al.
Publicado: (2023)

Changing patterns and clinical outcomes of hospitalized patients with COVID-19 severe pneumonia treated with remdesivir according to vaccination status: results from a real-world retrospective study
por: Mengato, Daniele, et al.
Publicado: (2023)

Correction to: Changing patterns and clinical outcomes of hospitalized patients with COVID‑19 severe pneumonia treated with remdesivir according to vaccination status: results from a real‑world retrospective study
por: Mengato, Daniele, et al.
Publicado: (2023)

Viro-immunological characterization of naïve patients with high cerebrospinal fluid (CSF) HIV RNA
por: Iannuzzi, Francesca, et al.
Publicado: (2014)

Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study
por: Chang, Hui-Min, et al.
Publicado: (2021)

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study
por: Giacomelli, Andrea, et al.
Publicado: (2021)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
por: Mazzitelli, Maria, et al.
Publicado: (2023)

Rapid Antigen Test LumiraDx(TM) vs. Real Time Polymerase Chain Reaction for the Diagnosis of SARS-CoV-2 Infection: A Retrospective Cohort Study
por: Cattelan, Anna Maria, et al.
Publicado: (2022)

COVID-19 Vaccination Limits Systemic Danger Signals in SARS-CoV-2 Infected Patients
por: Angioni, Roberta, et al.
Publicado: (2022)

Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report
por: Godinho, Rita, et al.
Publicado: (2019)

HIV infection with viro-immunological dissociation in a patient with polycystic kidney disease: Candidate for transplantation?
por: Colomba, Claudia, et al.
Publicado: (2016)

Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection
por: Mancon, A., et al.
Publicado: (2022)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

109. Preexisting Resistance and Week 48 Virologic Outcomes After Switching to B/F/TAF in African American Adults with HIV
por: Andreatta, Kristen, et al.
Publicado: (2020)

Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
por: DeJesus, E, et al.
Publicado: (2010)

Singular algebraic curves: with an appendix by Oleg Viro
por: Greuel, Gert-Martin, et al.
Publicado: (2018)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience
por: Mazzitelli, Maria, et al.
Publicado: (2022)

1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV
por: Hagins, Debbie, et al.
Publicado: (2020)

Consistent efficacy of B/F/TAF in treatment-naïve HIV patients across different baseline HIV-1 RNA levels at week 48
por: He, Kun, et al.
Publicado: (2023)

Predictors of immune reconstitution inflammatory syndrome associated with Kaposi’s sarcoma: a case report
por: Cattelan, Anna Maria, et al.
Publicado: (2016)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Turaev-viro invariant and 3N-J symbols
por: Carbone, G
Publicado: (1999)

Development of an elution device for ViroCap virus filters
por: Fagnant, Christine Susan, et al.
Publicado: (2017)

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
por: Zeng, Jiayi, et al.
Publicado: (2021)

Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy
por: Palanivelu, Lalitha, et al.
Publicado: (2023)

Prolonged SARS-CoV-2-RNA Detection from Nasopharyngeal Swabs in an Oncologic Patient: What Impact on Cancer Treatment?
por: Ferrari, Anna, et al.
Publicado: (2021)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

Demographical, Viro-Immunological, Clinical and Therapeutical Characteristics of HIV-Infected Patients in an “Epidemiologically Unexplored” Region of Italy (Calabria Region): the CalabrHIV Cohort
por: Postorino, Maria Concetta, et al.
Publicado: (2015)

Taf2 mediates DNA binding of Taf14
por: Klein, Brianna J., et al.
Publicado: (2022)

Signature Spanish BIC agreement
por: Bennett, Sophia Elizabeth
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qc9ee7l2k5mqk7lhipgfaiu9s8